Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is facing a challenging year in terms of sales growth due to the effects of the COVID-19 pandemic on the medical industry as well as ongoing regulatory hurdles. However, the company's well-managed expenses and an optimistic outlook for their natural healing-focused product portfolio present long-term potential for TELA Bio's financial success. While there may be near-term challenges, the company's commitment to prioritizing the preservation and restoration of the patient's anatomy sets TELA Bio apart in the competitive market of synthetic mesh manufacturers.

Bears say

TELA Bio is facing significant challenges as it continues to undergo a strategic overhaul and make changes to its sales team and commercial strategy. This has led to a lowered guidance for revenue growth, causing concern about the company's ability to execute and maintain stability in its sales force. There are also concerns about potential disruptions from these changes and a potential delay in reaching profitability. Furthermore, TELA Bio is heavily reliant on the success of its limited product portfolio, which may be impacted by reimbursement rates and competition in the market. Overall, these factors contribute to a negative outlook on the stock.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.